reason report
updat offer encourag signal small poc trial pt
financi result report posit pipelin updat two
intern pipelin program result come rel
small phase i/ii trial suggest proof concept
respect program justifi compani invest
late stage develop come month first phase
local activ oral pan-jak inhibitor new confirmatori
data ulcer coliti uc show evid effect high-
low-dos previous seen mid-dos see mid-
dose note link also minim system absorpt
even highest dose test otherwis well toler
reduct white blood cell count opportunist infect
treat patient safeti profil could becom product
ultim competit advantag replic phase iib/iii trial
uc commenc second therav report wholly-
own norepinephrin serotonin reuptak inhibitor nsri
demonstr encourag activ phase iia neurogen orthostat
hypotens noh trial syndrom sever disabl form
common postur hypotens occur context
gener neurolog disord includ parkinson diseas
pure autonom neuropathi affect mani patient
us character dizzi fall stand due
steep drop blood pressur led statist signific
blood pressur increas rapid sustain improv
valid postur dizzi symptom scale result difficult
fulli interpret come studi enrol patient
retain respond patient full period studi
observ updat model quarter continu
research revenu opportun asset
plan updat forecast come day preliminarili
assum po revenu trajectori match northera
current run-rat brand drug us market
noh continu believ therav royalti incom sale
gsk trelegi ellipta provid floor valuat stock least
potenti see note link
pipelin progress could meaning driver stock price
compani current valuat model updat quarter increas
price target retain outperform rate
stock
net debt total capit
dcf use dr tgr
compani inform leerink partner llc research
revenu million ep quarterli ep may total annual sum due chang share outstand
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform therav biotechnolog compani form via
spin-out thrx divers set asset robust engin
previous produc sever fda approv drug includ anoro breo vibativ
leverag deep expertis drug deliveri compani late earli stage pipelin
product oper via proven mechanisms-of-act aim differenti either
beneficial/us mode administr revefenacin better safeti /- wider therapeut
window one commerci product vibativ nich
antibiot commerci potenti fallen well short compani expect tbph
revefenacin nebul formul long act muscarin antagonist lama w/ posit
phase data patient partner op compani anticip
potenti us approv receiv signific share profit product
commerci passiv recipi stand earn net
royalti sale gsk close tripl trelegi recent approv
us europ prior medacorp survey work suggest success close tripl could
becom stapl copd standard-of-car model suggest tripl could becom
blockbust opportun temper slower-than-expect launch breo/anoro
still forecast ww tripl sale peak beyond tbph commercial/partn
asset compani also develop improv jak inhibitor jaki partner op
inflammatori bowel diseas ibd norepinephrin serotonin reuptak inhibitor
nsri neurogen orthostat hypotens noh drug leverag
novel deliveri uniqu compound proven mechanisms-of-act could offer
superior safeti and/or treatment effect wider therapeut window
data noh unlock new opportun believ high level investor
skeptic head phase iia readout noh announc data
amount definit proof concept suggest potenti util
nich condit like drug use condit induc increas blood
pressur reduc vasodil peripher blood pool chang posit
current brand drug noh northera sold us despit
fda label warn benefit demonstr past week therav
present data subgroup sicker noh patient dizzi score greater
scale show reduct point week data
corrobor statist signific increas blood pressur singl dose
improv probabl function benefit find aberr specif
systol blood pressur measur three-minut stand rel
benefit compar placebo believ level activ like
earn therav credit asset previous valu stock price
quick valu compar northera sole drug involv lundbeck purchas chelsea
therapeut year drug approv fda therav
conclud discuss fda phase trial design plan initi
program late earli believ could reach market
compani believ product exclus run
updat jak data confirm activ ulcer coliti uc compani save
detail phase ib data upcom gastroenterolog medic meet therav
qualit confirm dose cohort local jak inhibitor
replic efficaci seen last year mid-dos recal
patient trial enrol patient evenli arm
patient placebo therav state dose produc numer higher rate clinic
respons valid partial total mayo score system dose respons
observ meaning stringent measur efficaci base endoscop
improv observ three dose observ placebo
patient lack detail result frustrat rigor applic
endoscop verif activ central blind review endoscopi reassur
line compani collabor see note partnership valid
local jaki gut de-risk develop path therav intend start phase
induct mainten uc trial start phase ii poc studi crohn diseas
uc trial use dose compani believ
therapeut threshold maximum local gastrointestin tissu drug concentr
reach phase ib studi compani aim definit rule
dose provid clinic efficaci benefit rule
sub-optimal suggest fda still view studi requir confirm dose
rather pivot still wonder whether compani partner
requir conduct pivot trial adequ exposur select dose
dose file
balanc result price increas
therav report sale vibativ therav trelegi royalti
repres approxim gsk report sale
quarter trelegi continu strong launch gsk announc recent compani
priorit sale market resourc behind product sale grow therav
royalti stake increas tier manner therav burn
quarter remain cash secur avail manag reiter
guidanc oper loss ex share-bas comp approxim
annual cash burn follow updat financi result quarter manag
disclosur updat model specif push back revenu
year reflect like trial timelin chang time lower revenu
forecast base profil market opportun noh
increas revenu forecast later year increas total oper expens
forecast significantli reflect develop
cost loom late stage clinic trial well launch post launch commerci
expens forecast compani break even
although time becom shorter either activ molecul progress true
pivot trial base chang long-term outlook dcf base price target
increas reiter outperform rate therav stock
estim price target month use dcf analysi discount
rate termin growth rate discount rate consist model
biotech de-risk ph asset multipl program develop
higher risk aldr valuat inclus net cash
investor face multipl risk includ limit
commerci risk vibativ seen modest uptak thu far
commerci risk gsk trelegi close tripl combin well clinic risk label
signific clinic risk earli stage program given stage develop
partnership risk maxim opportun inflammatori bowel
develop risk sinc exploratori phase ii data enter pivot
dilut risk model equiti rais
believ could impact stock significantli
loss oper
loss incom tax
provis incom tax
share count period basic dilut
guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time
mid high dose
phase trial result
leerink partner research compani report present clinicaltri gov
pipelin program includ current model
pipelin program exclud current
non-ibd indic jak inhibitor
equival
chang
chg work cap
share outstand includ option warrant
